Biochemistry of Alzheimer's disease

Lore & Background

Alzheimer's disease is characterized by the accumulation of abnormally folded amyloid beta (Aβ) protein, a short peptide that is a proteolytic byproduct of the transmembrane protein amyloid-beta precursor protein (APP). At sufficiently high concentration, Aβ monomers undergo a conformational change to form beta sheet-rich tertiary structures that aggregate into amyloid fibrils, depositing outside neurons as senile plaques. These plaques include diffuse, compact, cored, and neuritic types, as well as deposits in blood vessel walls known as cerebral amyloid angiopathy.

AD is also a tauopathy, involving hyperphosphorylated tau protein that accumulates as paired helical filaments, forming neurofibrillary tangles inside nerve cell bodies and dystrophic neurites associated with amyloid plaques. Neuroinflammation is involved in the pathology, with increased pro-inflammatory cytokine concentrations in blood and cerebrospinal fluid, and increased reactivity of microglia towards amyloid deposits.

At a macroscopic level, AD involves loss of neurons and synapses in the cerebral cortex and subcortical regions, leading to atrophy of the temporal lobe, parietal lobe, frontal cortex, and cingulate gyrus. Both amyloid plaques and neurofibrillary tangles are visible by microscopy, with AD brains having them to a much greater extent and in different locations than in normal aging.

Reader's Guide

The biochemistry of Alzheimer's disease centers on two key protein abnormalities: amyloid beta aggregation and tau hyperphosphorylation. Amyloid beta monomers, normally harmless, form beta sheet-rich fibrils that deposit as senile plaques outside neurons. Tau protein, which stabilizes microtubules, becomes hyperphosphorylated and forms paired helical filaments that aggregate into neurofibrillary tangles inside nerve cells. These processes are accompanied by neuroinflammation, with increased pro-inflammatory cytokines and microglial reactivity. The disease leads to gross atrophy of brain regions including the temporal and parietal lobes. While the amyloid hypothesis is dominant among researchers, the tau hypothesis is supported by the observation that amyloid plaque deposition does not correlate well with neuron loss. The cholinergic hypothesis, suggesting deficiency in cholinergic signaling, is among the oldest. Levels of neurotransmitters such as acetylcholine are reduced, and anti-cholinesterases are an approved treatment. The disease is not transmissible in the wild, though extremely rare iatrogenic events from donor-derived therapies have been noted. Understanding these biochemical events is fundamental to comprehending AD pathology.

Did You Know?

• Alzheimer's disease is identified as both a proteopathy (due to amyloid beta) and a tauopathy (due to tau protein).
• Amyloid beta monomers are largely alpha helical in membranes but undergo a conformational change to beta sheet-rich structures at high concentration.
• Hyperphosphorylated tau accumulates as paired helical filaments that form neurofibrillary tangles inside nerve cell bodies.
• Levels of the neurotransmitter acetylcholine are reduced in Alzheimer's disease, and anti-cholinesterases are an approved treatment.

The Amyloid Cascade and Protein Misfolding

Alzheimer's disease is fundamentally a proteopathy, a condition driven by the misfolding and accumulation of a specific protein. At the heart of this process lies amyloid-beta (Aβ), a short peptide generated as an abnormal byproduct when the transmembrane protein amyloid-beta precursor protein (APP) is cleaved. APP's precise biological role remains uncertain, though researchers suspect it plays a part in neuronal development. The presenilins, integral components of the proteolytic complex responsible for APP processing and degradation, sit at a critical juncture in this pathway. In their monomeric, soluble form, Aβ molecules carry short stretches of beta-sheet and polyproline II helix secondary structure in solution, while adopting a predominantly alpha-helical conformation when embedded in membranes. However, once concentrations climb high enough, these monomers undergo a dramatic structural reorganization into a beta-sheet-rich tertiary architecture. This conformational shift triggers aggregation into amyloid fibrils, which then deposit outside neurons as the hallmark senile plaques. These deposits manifest in several morphological variants, including diffuse plaques, compact plaques, and cored or neuritic plaques, and can even infiltrate the walls of small cerebral blood vessels in a condition termed cerebral amyloid angiopathy.

Tau Aggregation and Neurofibrillary Tangles

Beyond amyloid pathology, Alzheimer's disease is simultaneously classified as a tauopathy, a second axis of protein misfolding that strikes from within the neuron. Tau is a microtubule-associated protein expressed in neurons, and its normal job is to stabilize the microtubule networks that form the cell's cytoskeletal scaffolding. Under healthy conditions, tau activity is modulated through phosphorylation, a standard regulatory mechanism shared by most microtubule-associated proteins. In Alzheimer's disease, however, this regulation breaks down: tau becomes hyperphosphorylated, and the excess modified protein assembles into paired helical filaments. These filaments then clump together into dense intracellular masses called neurofibrillary tangles within nerve cell bodies, and they also appear as dystrophic neurites clustered around amyloid plaques. The precise molecular steps governing filament assembly remain poorly understood, but one clue has emerged: depletion of a prolyl isomerase belonging to the parvulin family has been shown to accelerate the buildup of abnormal tau, hinting at a regulatory role for this protein family in keeping tau in its proper conformational state.

Neuroinflammation and the Immune Dimension

A third layer of Alzheimer's biochemistry involves the brain's immune response, which is increasingly recognized as a participant in the disease cascade rather than a mere bystander. Pathological and clinical data consistently document immunological alterations in Alzheimer's patients, including elevated concentrations of pro-inflammatory cytokines detectable in both peripheral blood and cerebrospinal fluid. Within the brain itself, resident microglial cells, the tissue's innate immune sentinels, show heightened reactivity toward amyloid deposits, suggesting that the inflammatory milieu is woven into the pathogenesis and progression of the disease. A critical unresolved question is whether this neuroinflammation acts as a primary driver of neuronal damage or whether it represents a secondary, compensatory response to the accumulating amyloid and tau pathology. The evidence points to a complex, bidirectional relationship in which immune signaling and protein aggregation feed into one another, amplifying the cascade of cellular dysfunction. Much of what is known about these interconnected biochemical events has been uncovered through the use of experimental disease models, which continue to serve as essential tools for dissecting the molecular choreography of Alzheimer's.

Neurotransmitter Deficits and Therapeutic Strategies

The biochemical signature of Alzheimer's extends beyond protein aggregation to include a marked reduction in key neurotransmitters. Acetylcholine (ACh) levels are notably diminished, and this deficit is accompanied by decreased levels of serotonin, norepinephrine, and somatostatin in affected brains. Because of this cholinergic shortfall, replenishing ACh through anti-cholinesterase medications has become an FDA-approved treatment strategy for managing symptoms. Looking ahead, researchers have proposed a next-generation cholinomimetic approach: synthetic agonists designed to stimulate M1 through M3 acetylcholine receptor subtypes with a slower dissociation rate from the receptor, potentially offering more sustained signaling. On the enzymatic front, a delicate balance among the secretase family of enzymes governs how much amyloid-beta accumulates, and recent work has highlighted a link between cholinergic neuronal activity and alpha-secretase function, which appears to discourage Aβ deposition in the brain. Abnormal Aβ accumulation can be detected early through cerebrospinal fluid analysis and later visualized using positron emission tomography, providing a biochemical window into disease progression.